FDA Pushes Drug Developers to Report Clinical Trial Results

Agency sends over 2,200 letters pressing companies to publish data they've failed to report

Apr. 13, 2026 at 5:56pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the internal structure of a pill capsule against a dark background, conceptually illustrating the importance of transparency in clinical trial reporting.An X-ray view exposes the hidden inner workings of a pharmaceutical product, underscoring the need for full transparency in clinical trial data.NYC Today

The Food and Drug Administration announced it has sent over 2,200 letters to drug manufacturers, medical device makers, and researchers, pressing them to publish clinical trial data that they have failed to report as legally required. The FDA says this lack of transparency can mislead doctors and patients, and hinder scientific progress.

Why it matters

For years, many drug developers have not reported clinical trial results as legally mandated, with an internal FDA analysis finding around 30% of studies examined had not reported their results. This lack of transparency can lead to doctors and patients being misled about a drug's efficacy, and prevents scientists from accurately determining whether further development of a treatment is warranted.

The details

The FDA will formally announce the letters on Monday, saying companies sometimes suppress negative results that could look unfavorable. While the agency is asking researchers and companies to voluntarily submit their results, some experts argue the FDA should use stronger enforcement tools it has, like fines of over $10,000 per day for non-compliance. The agency says this is a first step, and it plans to send more formal warnings in the future.

  • The FDA will announce the letters on Monday, April 13, 2026.
  • In 2007, Congress passed a law mandating clinical trial results reporting after the Vioxx scandal.

The players

Dr. Marty Makary

FDA Commissioner who said companies have a "moral duty" to report clinical trial results, and that the lack of transparency is a "public health issue".

Christopher Morten

Director of the Science, Health and Information Clinic at the New York University School of Law, who petitioned the FDA in 2023 to ramp up enforcement of universities and companies that did not report trial results.

Holly Fernandez Lynch

Associate professor of medical ethics and health policy at the University of Pennsylvania, who said the reporting requirement is "a critically important scientific and ethical requirement" and criticized the FDA's "pretty please" approach.

Dr. Reshma Ramachandran

Assistant professor at Yale Medicine who worked with Morten to petition the FDA.

Merck

The maker of the arthritis medication Vioxx, which was withdrawn from the market after a high-profile scandal involving the company's handling of data showing the drug was associated with an increased risk of heart attack.

Got photos? Submit your photos here. ›

What they’re saying

“What I want to see is companies do the right thing and realize the moral duty they have.”

— Dr. Marty Makary, FDA Commissioner

“This is not just some kind of paper-pushing bureaucratic requirement. It's actually a critically important scientific and ethical requirement.”

— Holly Fernandez Lynch, Associate professor of medical ethics and health policy, University of Pennsylvania

“Just drop the hammer on this. No more notice is needed.”

— Holly Fernandez Lynch, Associate professor of medical ethics and health policy, University of Pennsylvania

What’s next

The FDA says it plans to send more formal warnings, known as letters of noncompliance, to companies that fail to report clinical trial results in the future. The agency is also using artificial intelligence and other technology to screen for non-compliance.

The takeaway

This action by the FDA highlights the ongoing issue of transparency in clinical trials, and the need for stronger enforcement to ensure drug developers fulfill their legal and ethical obligations to report trial results. Improving data reporting can help doctors make more informed decisions and advance medical research, but will require the FDA to take a firmer stance against non-compliance.